SECURED LIFI (SECURED VISIBLE LIGHT COMMUNICATION)

Future electric lights will be comprised of white LEDS (light emitting diode).White led’s with high power output are expected to serve in the next generation of lamps. An indoor visible data transmission system utilizing white led lights is proposed. In the system, these devices are used not only for illuminating rooms but also for an optical wireless communication system. This system is suitable for private networks such as consumer communication networks. However it remains necessary to investigate the properties of white led’s when they are used as optical transmitters. Based on numerical analyses and computer simulations it can be used for indoor optical transmission.Moreover secured transmission is possible using steganography and password prompt for exchang

Ecosystem health assessment of Sungai Pengkalan Chepa Basin: water quality and heavy metal analysis

This study was to determine the ecosystem health status at Sungai Pengkalan Chepa Basin based on Water Quality Index (WQI) and heavy metal concentration in the river water. Water samples were collected from 11 stations along the river and they were analyzed using YSI 556 MPS and laboratory analysis for in-situ test and ex-situ test, respectively. Meanwhile, heavy metal concentrations were analyzed using AAS. Water sampling was carried out starting from November 2018 until June 2019. The results for total median value of water quality parameters were as follows; DO (2.72 mg/L), BOD (6.42 mg/L), COD (33.5 mg/L), AN (1.02 mg/L), TSS (27 mg/L), and pH (6.97). According to WQI, Sungai Pengkalan Chepa Basin is classified under Class III, therefore, it is considered as slightly polluted. The order of concentration of heavy metals in water is Fe > Cr > Zn > Cu > Cd. Most of the heavy metals were found within the permitted level of National Drinking Water Quality Standard (NDWQS) except for Cd. Based on the Kruskal Walis test, there was a significant difference between parameters namely DO, BOD, COD, AN, pH, Zn, and Cd with sampling locations (ρ < 0.05). Based on this study, it can be concluded that the ecosystem health of Sungai Pengkalan Chepa Basin is not healthy from the aspects of DO, BOD, COD, AN, and Cd. The water quality status of Sungai Pengkalan Chepa Basin was mainly affected by the anthropogenic activities from urban development

Proteins from Avastin® (bevacizumab) Show Tyrosine Nitrations for which the Consequences Are Completely Unclear

Avastin® (bevacizumab) is a protein drug widely used for cancer treatment although its further use is questionable due to serious side effects reported. As no systematic proteomic study on posttranslational modifications (PTMs) was reported so far, it was the aim of the current study to use a gel-based proteomics method for determination of Avastin®-protein(s)

Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature

Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor which has been used in conjunction with other anti-cancer agents in the treatment of patients with many cancers. It remains controversial whether bevacizumab can prolong survival in cancer patients. This meta-analysis was therefore performed to evaluate effect of bevacizumab on survival in cancer patients. PubMed, EMBASE, and Web of Science databases were searched for English-language studies of randomized controlled trials comparing bevacizumab with control therapy published through February 8, 2012. Progression-free survival, overall survival, and one-year survival rate were analyzed using random- or fixed-effects model. Thirty one assessable randomized controlled trials were identified. A significant improvement in progression-free survival in cancer patients was attributable to bevacizumab compared with control therapy (hazard ratio, 0.72; 95% confidence interval, 0.68 to 0.76; p<0.001). Overall survival was also significantly longer in patients were treated with bevacizumab (hazard ratio, 0.87; 95% confidence interval, 0.83 to 0.91; p<0.001). The significant benefit in one-year survival rate was further seen in cancer patients receiving bevacizumab (odds ratio, 1.30; 95% confidence interval, 1.20 to 1.41; p<0.001). Current evidences showed that bevacizumab prolong progression-free survival and overall survival, and increase one-year survival rate in cancer patients as compared with control therapy